Sinomenine ameliorates arthritis via MMPs, TIMPs, and cytokines in rats

Biochemical and Biophysical Research Communications

Volumn 376, Issue 2, 2008, Pages 352-357

  Zhou, Hua ^a   Wong, Yuen Fan ^a   Wang, Jue ^a   Cai, Xiong ^a   Liu, Liang ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

Collagen induced arthritis; Cytokines; MMPs; Sinomenine; TIMPs

Indexed keywords

COLLAGEN TYPE 2; GELATINASE A; GELATINASE B; INDOMETACIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; SINOMENINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SINOMENIUM; SINOMENIUM ACUTUM;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; FEMALE; INTERLEUKIN-1BETA; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MORPHINANS; RATS; RATS, WISTAR; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

MENISPERMACEAE; RATTUS; RATTUS NORVEGICUS; SINOMENIUM ACUTUM;

EID: 52949088275     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.08.153     Document Type: Article

References (34)

1. Gabriel S.E. The epidemiology of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 27 (2001) 269-281
2. Choy E.H., and Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344 (2001) 907-916
3. Maini R.N., and Taylor P.C. Anti-cytokine therapy for rheumatoid arthritis. Annu. Rev. Med. 51 (2000) 207-229
4. Burrage P.S., Mix K.S., and Brinckerhoff C.E. Matrix metalloproteinases: role in arthritis. Front. Biosci. 11 (2006) 529-543
5. Cawston T.E. Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol. Ther. 70 (1996) 163-182
6. Burger D., Rezzonico R., Li J.M., Modoux C., Pierce R.A., Welgus H.G., and Dayer J.M. Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: involvement of membrane-associated cytokines. Arthritis Rheum. 41 (1998) 1748-1759
7. Simon L.S. DMARDs in the treatment of rheumatoid arthritis: current agents and future developments. Int. J. Clin. Pract. 54 (2000) 243-249
8. Kremer J.M. Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin. Arthritis Rheum. 29 (1999) 14-26
9. Lee D.M., and Weinblatt M.E. Rheumatoid arthritis. Lancet 358 (2001) 903-911
10. Chen K.J., and Chen T.T. Chinese Medical Herbology and Pharmacology (2001), Art of Medicine Press, Inc., City of Industry, CA, USA
11. K.C. Wong, L.T. Wu, History of Chinese Medicine, second ed., National Quarantine Service, Shanghai, China, 1936, p. 119.
12. Hua H., and Chen X. Mechanistic study of sinomenine on analgesic and anti-inflammatory actions. J. Xian Medical University 4 (1989) 346-349
13. Liu L., Buchner E., Beitze D., Schmidt-Weber C.B., Kaever V., Emmrich F., and Kinne R.W. Amelioration of rat experimental arthritides by treatment with the alkaloid sinomenine. Int. J. Immunopharmacol. 18 (1996) 529-543
14. Wang Y., Fang Y., Huang W., Zhou X., Wang M., Zhong B., and Peng D. Effect of sinomenine on cytokine expression of macrophages and synoviocytes in adjuvant arthritis rats. J. Ethnopharmacol. 98 (2005) 37-43
15. Rosloniec E., Cremer M., Kang A., and Myers L. Animal models for autoimmune and inflammatory disease: collagen-induced arthritis. In: Colagin J.E. (Ed). Current Protocols in Immunology (1994), John Wiley, New York Unit
16. Bull B., Caswell M., Ernst E., Kallner A., Koepke J., Lewis S., Rampling M., and Stuart J. ICSH recommendations for measurement of erythrocyte sedimentation rate. International council for standardization in haematology (expert panel on blood rheology). J. Clin. Pathol. 46 (1993) 198-203
17. Funada Y., Nishimura Y., and Yokoyama M. Imbalance of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 is associated with pulmonary emphysema in Klotho mice. Kobe J. Med.Sci. 50 (2004) 59-67
18. Oliver G.W., Leferson J.D., Stetler-Stevenson W.G., and Kleiner D.E. Quantitative reverse zymography: analysis of picogram amounts of metalloproteinase inhibitors using gelatinase A and B reverse zymograms. Anal. Biochem. 244 (1997) 161-166
19. Liu L., Riese J., Resch K., and Kaever V. Impairment of macrophage eicosanoid and nitric oxide production by an alkaloid from Sinomenium acutum. Arzneimittelforschung 44 (1994) 1223-1226
20. Liu L., Resch K., and Kaever V. Inhibition of lymphocyte proliferation by the anti-arthritic drug sinomenine. Int. J. Immunopharmacol. 16 (1994) 685-691
21. Alarcon G.S. Epidemiology of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 21 (1995) 589-604
22. Arend W.P., and Dayer J.M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum. 38 (1995) 151-160
23. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14 (1996) 397-440
24. Tamura T., Udagawa N., Takahashi N., Miyaura C., Tanaka S., Yamada Y., Koishihara Y., Ohsugi Y., Kumaki K., and Taga T. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc. Natl. Acad. Sci. USA 90 (1993) 11924-11928
25. Ohshima S., Saeki Y., Mima T., Sasai M., Nishioka K., Nomura S., Kopf M., Katada Y., Tanaka T., Suemura M., and Kishimoto T. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc. Natl. Acad. Sci. USA 95 (1998) 8222-8226
26. Alonzi T., Fattori E., Lazzaro D., Costa P., Probert L., Kollias G., De B.F., Poli V., and Ciliberto G. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187 (1998) 461-468
27. Choy E.H., Isenberg D.A., Garrood T., Farrow S., Ioannou Y., Bird H., Cheung N., Williams B., Hazleman B., Price R., Yoshizaki K., Nishimoto N., Kishimoto T., and Panayi G.S. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 46 (2002) 3143-3150
28. Elliott M.J., Maini R.N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F.M., Walker J., Bijl H., and Ghrayeb J. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 36 (1993) 1681-1690
29. Joosten L.A., Helsen M.M., Saxne T., van De Loo F.A., Heinegard D., and van Den Berg W.B. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J. Immunol. 163 (1999) 5049-5055
30. Emonard H., and Grimaud J.A. Matrix metalloproteinases. A review. Cell. Mol. Biol. 36 (1990) 131-153
31. Yoshihara Y., Nakamura H., Obata K., Yamada H., Hayakawa T., Fujikawa K., and Okada Y. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann. Rheum. Dis. 59 (2000) 455-461
32. Morel J., and Berenbaum F. Signal transduction pathways: new targets for treating rheumatoid arthritis. Joint Bone Spine 71 (2004) 503-510
33. Lin T., Zhang W., Fan Y., and Mulholland M. Interleukin-1beta and interleukin-6 stimulate matrix metalloproteinase-9 secretion in cultured myenteric glia. J. Surg. Res. 137 (2007) 38-45
34. Di G.N., Indoh I., Jackson N., Wakefield D., McNeil H.P., Yan W., Geczy C., Arm J.P., and Tedla N. Human mast cell-derived gelatinase B (matrix metalloproteinase-9) is regulated by inflammatory cytokines: role in cell migration. J. Immunol. 177 (2006) 2638-2650